立方制药(003020.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理

Core Viewpoint - Company received acceptance notification for drug registration applications for Dapagliflozin Metformin Extended-Release Tablets (I, II, III) from the National Medical Products Administration [1] Company Summary - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation consisting of SGLT2 inhibitor Dapagliflozin and the biguanide drug Metformin [1] - The combination aims to provide comprehensive and effective blood glucose control for adult patients with type 2 diabetes [1] Industry Summary - The product is co-developed by Bristol-Myers Squibb Company and AstraZeneca AB [1] - As of the announcement date, eight domestic companies have received approval for similar products, excluding imported ones [1]